Cytotoxic, cytostatic and HIV-1 PR inhibitory activities of the soft coral litophyton arboreum by Ellithey, Mona S. et al.
Mar. Drugs 2013, 11, 4917-4936; doi:10.3390/md11124917 
 
marine drugs  
ISSN 1660-3397 
www.mdpi.com/journal/marinedrugs 
Article 
Cytotoxic, Cytostatic and HIV-1 PR Inhibitory Activities of the 
Soft Coral Litophyton arboreum 
Mona S. Ellithey 
1
, Namrita Lall 
2
, Ahmed A. Hussein 
3
 and Debra Meyer 
1,
* 
1
 Department of Biochemistry, University of Pretoria, Pretoria 0002, South Africa;  
E-Mail: u12000541@tuks.co.za 
2
 Department of Plant Science, University of Pretoria, Pretoria 0002, South Africa;  
E-Mail: Namrita.Lall@up.ac.za 
3
 Department of Chemistry, University of the Western Cape, Private Bag X17, Belleville 7535,  
South Africa; E-Mail: ahmohammed@uwc.ac.za 
* Author to whom correspondence should be addressed; E-Mail: Debra.Meyer@up.ac.za;  
Tel.: +27-12-420-2300; Fax: +27-12-362-5302. 
Received: 24 September 2013; in revised form: 18 November 2013 / Accepted: 19 November 2013 /  
Published: 10 December 2013 
 
Abstract: Bioassay-guided fractionation using different chromatographic and 
spectroscopic techniques in the analysis of the Red Sea soft coral Litophyton arboreum  
led to the isolation of nine compounds; sarcophytol M (1), alismol (2),  
24-methylcholesta-5,24(28)-diene-3β-ol (3), 10-O-methyl alismoxide (4), alismoxide (5), 
(S)-chimyl alcohol (6), 7β-acetoxy-24-methylcholesta-5-24(28)-diene-3,19-diol (7), 
erythro-N-dodecanoyl-docosasphinga-(4E,8E)-dienine (8), and 24-methylcholesta-5,24 
(28)-diene-3β,7β,19-triol (9). Some of the isolated compounds demonstrated potent 
cytotoxic- and/or cytostatic activity against HeLa and U937 cancer cell lines and inhibitory 
activity against HIV-1 protease (PR). Compound 7 was strongly cytotoxic against HeLa 
cells (CC50 4.3 ± 0.75 µM), with selectivity index of SI 8.1, which was confirmed by real 
time cell electronic sensing (RT-CES). Compounds 2, 7, and 8 showed strong inhibitory 
activity against HIV-1 PR at IC50s of 7.20 ± 0.7, 4.85 ± 0.18, and 4.80 ± 0.92 µM 
respectively. In silico docking of most compounds presented comparable scores to that of 
acetyl pepstatin, a known HIV-1 PR inhibitor. Interestingly, compound 8 showed potent 
HIV-1 PR inhibitory activity in the absence of cytotoxicity against the cell lines used. In 
addition, compounds 2 and 5 demonstrated cytostatic action in HeLa cells, revealing 
potential use in virostatic cocktails. Taken together, data presented here suggest Litophyton 
arboreum to contain promising compounds for further investigation against the  
diseases mentioned. 
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Abbreviation 
XTT, (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide); ART, Antiretroviral 
therapy; HAART, highly active antiretroviral therapy; SI, Selectivity index; RT-CES, Real time cell 
electronic sensing; CI, cell index; AP, acetyl pepstatin; EIMS, Electron ionized mass spectrometry. 
1. Introduction 
HIV/AIDS is one of the most devastating diseases in the world with approximately 34 million 
people living with the virus in 2010 and approximately 2.7 million new infections in that same  
year [1]. Antiretroviral therapy (ART) successfully reduces infection and decreases symptoms; but, the 
emergence of viral drug resistance, due to drug-induced mutations in viral genes, renders treatment 
ineffective. This underscores an urgent need to develop new anti-HIV drugs [2,3] with fewer  
side-effects to improve patient compliance. 
The use of anti-HIV drugs as cancer treatments is not new. Azidothymidine was studied as an 
antineoplasic in the 1990s, but despite promising in vitro data, clinical trials showed little antitumor 
activity. HIV protease inhibitors were developed in the early 1990s, and their subsequent incorporation 
into highly active antiretroviral therapy (HAART) has profoundly changed the natural history of HIV 
infection. The potential antitumor properties of these drugs have been investigated because of their 
success in treating HIV-related Kaposi’s sarcoma. HAART’s effects on Kaposi’s sarcoma did not 
always correlate with immune reconstitution, and activity against other solid and haematological 
malignancies has been established. Inhibition of tumor-cell invasion and angiogenesis were properties 
first ascribed to HIV protease inhibitors; these drugs have pleiotropic antitumor effects, including 
inhibition of inflammatory cytokine production, proteasome activity, cell proliferation and survival, 
and induction of apoptosis. HIV protease inhibitors are thus a new class of anticancer drugs with 
multiple effects, and other anti-HIV drugs might hold similar promise [4]. 
Marine organisms as a source of natural products delivered numerous novel compounds with 
sensational multiple pharmacological properties. During the past 20 years, thousands of novel 
compounds and their metabolites with diverse biological activities ranging from antiviral to anticancer 
have been isolated from various marine sources. The use of marine natural products as anti-HIV agents 
has also been described [5] with a number of potential lead compounds identified. In computational 
science, natural products have long captured the attention of medicinal chemists due to the diversity of 
their chemical scaffolds, potentially lower toxicities and bioactive substructures [6]. 
The Red Sea still contains a large number of uninvestigated organisms (flora and fauna). 
Exploration of untapped regions of this unique resource for the discovery of bioactive natural 
compounds is an urgent task due to the impending environmental changes that can occur to the wild 
flora as human encroachment continues. Litophyton arboreum is a common octocoral, widely 
distributed on the Red Sea coral reefs. A previous chemical study of L. arboreum growing in different 
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parts of the Red Sea showed the presence of cembranoide diterpenes [7], which had moderate 
cytotoxicity in HeLa cells. Collections of this soft coral from other parts of the world showed different 
metabolites of this soft coral, e.g., furanocembranoides, which demonstrated antiproliferative activities 
against the cell lines L-929 and K-562 [8], sesquiterpenes, sterols, and fatty acid derivatives [9,10] all 
believed to contain medicinal properties. Herein, we report on the isolation and identification of nine 
compounds from L. arboreum collected from Sharm El-Sheikh, Red Sea. The anti-HIV and anti-cancer 
potential of some of the purified compounds from the soft coral is reported here for the first time. 
2. Results and Discussion 
2.1. Bioactivity of Isolated Compounds 
When screening several Red sea marine organisms for biological activity, an ethyl acetate fraction 
of L. arboreum demonstrated very strong cytotoxicity in U937 (IC50 6.50 ± 2.3 µg/mL) and moderate 
cytotoxicity (IC50 28.10 ± 1.2 µg/mL) in HeLa cell lines. The fraction also showed strong HIV-1 PR 
inhibitory activity (IC50 12 ± 1.3 µg/mL). These results provided justification for further chemical 
investigation of the lipophilic extract. Activities of the extract were characterized as discussed in  
Le Roux et al., 2011 [11]. 
The chromatographic process yielded 20 major fractions. The cytotoxicity of the extract in U937 
cells was used to direct the bioassay-guided fractionation. U937 is one of the most resistant cancer cell 
lines. Anti-cancer drugs and HIV treatment are related since nucleotide analogs can be used for the 
treatment of both medical conditions making it possible for the same extracts to contain compounds 
active against both. Figure 1 shows that, between the twenty fractions, only fractions 5–8, 12, 14, 15, 
and 20 were 100% cytotoxic in U937 cell line when tested at a concentration of 100 µg/mL. Fractions 
16–19 did not show any toxicity in the cells. 
Figure 1. Cytotoxicity of L. arboreum main fractions tested in U937 cells at 100 µg/mL. 
 
Further fractionation and purification of the active fractions resulted in the isolation and 
identification of nine known compounds (for which the structures are provided in Figure 2)  
isolated for the first time from this organism sarcophytol M (1) [12], alismol (2) [13,14],  
-5 
0 
5 
10 
15 
20 
25 
30 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F20 
V
ia
b
il
it
y
 o
f 
T
re
a
te
d
 C
el
ls
 
Fractions 
Mar. Drugs 2013, 11 4920 
 
 
24-methylcholesta-5,24(28)-diene-3β-ol (3) [15], 10-O-methyl alismoxide (4) [13,16],  
alismoxide (5) [13,14], (S)-chimyl alcohol (6) [17], 7β-acetoxy-24-methylcholesta-5-24 
(28)-diene-3,19-diol (7) [18], erythro-N-dodecanoyl-docosasphinga-(4E,8E)-dienine (8) [19], and  
24-methylcholesta-5,24(28)-diene-3β,7β,19-triol (9) [20]. 
Figure 2. Chemical structure of L. arboreum isolated compounds. 
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Compound 1 known as sarcophytol M (or serratol), was isolated for the first time in a high yield 
from Boswellia serrata [12] and it showed activity against Trypanosoma brucei and Plasmodium 
falciparum [16]. Compounds 2, 4, and 5 are rare metabolites, identified as active constituents found in 
extracts from Alismatis rhizome [12,14,16]. Compound 2 was found to inhibit the vascular contraction 
of rabbit thoracic aorta through increasing Ca
2+
 retention [21,22]. It demonstrated antihypertensive 
potential [23], and showed promising inhibitory effects on INF-γ-induced nitric oxide production in 
murine macrophage RAW264.7 cells [24]. Compound 3 was previously isolated from the soft coral 
Sinularia gibberosa of Kenting coast, Taiwan but there are no reports on its biological activities. This 
study is the first report on the isolation of compound 4 and the second report of compounds 2 and 5 
from marine resources [8], and it is the first report of the HIV-1 enzyme inhibitory activities of most of 
these compounds, as well as the cytotoxicity in HeLa and U937 cancer cell lines. 
2.2. Cytotoxicity 
The responses of the isolated compounds were characterized according to P. Prayong et al.,  
(2008) [25], where an IC50 value of <5 µg/mL for a pure compound is viewed as strongly cytotoxic. A 
selectivity index >3 indicates high selectivity [26]. SI values were calculated as follows: IC50 of the 
extract tested in the Vero cell line/IC50 of the extract tested in the cancer cell. The inhibitory 
concentrations and selectivity indices of the isolated nine compounds shown in Table 1 showed that, 
steroids (7β-acetoxy-24-methylcholesta-5-24(28)-diene-3,19-diol (7) and 24-methylcholesta-5,24 
(28)-diene-3β,7β,19-triol (9)) showed the highest cytotoxicity among the isolated compounds. 
Compound 7 demonstrated strong cytotoxicity and selectivity (IC50 5.3 ± 0.60 µM (4.3 µg/mL), SI 7.2) 
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in HeLa cells and high selectivity with moderate cytotoxicity (IC50 10.6 ± 0.12 µM (7.8 µg/mL),  
SI 2.9) in U937 cells. Compound 9 showed similar results with strong cytotoxicity (IC50 8 ± 0.5 µM 
(3.4 µg/mL) but moderate selectivity (SI 1.4)) in HeLa cells and moderate cytotoxicity  
(IC50 16.4 ± 1.25 µM and moderate selectivity (SI 1.3)) in U937 cells. 
Table 1. Cytotoxic inhibitory concentrations, selectivity indexes and HIV-1 PR inhibitory 
concentrations of the nine isolated compounds in different cell lines. 
Compound Cytotoxicity IC50 (µM) SI Values IC50 (µM) 
 
HeLa Vero U937 HeLa U937 HIV-1 PR 
1 27.5 ± 0.2 22 ± 0.2 31.7 ± 3.2 0.8 0.75 15.7 ± 0.10 
2 30 ± 17.2 49 N/T 1.6 N/T 7.2 ± 0.7 
3 48 ± 8.7 100 ± 1.2 N/T 2.1 N/T N/T 
4 38 ± 0.7 49.8 ± 0.5 50 ± 0.23 1.3 1.00 N/T 
5 >100 >100 >100 ± 0.04 N/A N/A N/T 
6 23.35 ± 5.8 60 ± 1.14 N/T 2.6 N/T 26.6 ± 2.6 
7 5.3 ± 0.6 31.3 ± 14.03 10.6 ± 0.12 7.2 2.9 4.85 ± 0.18 
8 38.17 ± 0.7 >100 N/T 2.6 2.95 4.8 ± 0.92 
9 8 ± 0.5 11.4 ± 0.04 16.4 ± 1.25 1.4 1.3 N/T 
Positive control 
 
    
 
Actinomycin D 5.1 ± 0.1 8.8 ± 2.5 1.9 ± 0.865 1.7 4.72 
 
Acetyl pepstatin      8.5 ± 0.72 
N/T: Not tested compounds (inhibitory % < 60% for PR inhibition and <80% cytotoxic). 
7β-acetoxy-24-methylcholesta-5-24(28)-diene-3,19-diol (7) from the soft coral Nephthea chabroli 
and compound 9 from the soft coral Litophyton virides showed sp. comparable cytotoxic activity for 
tests against different human cancer cell lines; the compounds showed cytotoxicity against human 
prostate cancer cell line LNCaP with IC50 of 15.5 and 4.9 µg/mL [27], A549 cancer cell lines (0.81, 
0.69 µg/mL), HT-29 (0.87, 0.72 µg/mL), KB (0.38, 0.58 µg/mL), P-388 (0.42, 0.24 µg/mL) [28] 
(activities for compound 7 are presented first followed by activity of compound 9). Activity against 
Mycobacterium tuberculosis was reported for compound 9 [29], as was an immunosuppressive  
ction [30]. In addition, 24-methylcholesta-5,24(28)-diene-3β,7β,19-triol (9) showed preventive action 
against lipid peroxidation when mixed with different tissue homogenates in vivo [31]. The changing of 
functional groups of compounds 7 and 9, especially at C-19 in addition to the 5-ene B ring, which is 
normally observed in an 8β, 9α-half-chair conformations [32], contributed strongly to the final activity 
and the mode of interaction with the cell membranes. However, there are small differences in the 
activity of these compounds which stem from the blocking of the hydroxyl group at C-7 (compound 7) 
and thus increases the lipophilicity character of the compound. This supports the effect of lipophilicity 
on the biological activities as it controls the ability of a drug to penetrate various biological 
membranes, tissues, or barriers and represents a primary factor in controlling the interaction of drugs 
with biological systems [33]. 
Moderate cytotoxicity was shown by compound 1 (IC50 27.5 ± 0.2 µM (8.1 µg/mL), SI 0.8). The 
rest of the compounds showed weak cytotoxicity (>10 µg/mL) compared to Actinomycin D IC50s  
(5.1 ± 0.1 µM for HeLa, 8.8 ± 2.5 µM for Vero, and 1.9 ± 0.87 μM for U937). 
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2.3. Real Time Cell Analysis 
Compound cytotoxicity was investigated further by confirmatory assays in HeLa cells, involving 
no-label real time cell analysis. Figure 3 shows the real time cell analyses for compounds 7 and 9, 
which confirmed their cytotoxic effects when tested at IC50s obtained by the end point assay XTT in 
the same cell line (4.3 µM and 8 µM, respectively). 
Figure 3. Comparison of RT-CES data of compounds 7β-acetoxy-24-methylcholesta-5-24 
(28)-diene-3,19-diol (7) and 24-methylcholesta-5,24(28)-diene-3β,7β,19-triol (9) showing 
cytotoxicity profiles in HeLa cells. The compounds were more toxic than the positive 
control, Actinomycin D. 
 
Further dose effects of compound 7 in HeLa cells (shown in Figure 4) were evaluated by testing the 
compound’s cytotoxic effect at 10, 5, and 2.5 µg/mL (13.4, 6.73, 3.36 µM). At 10 and 5 μg/mL, the 
compound initially underwent an uptake phase and then presented a dose dependent cytotoxic response 
for the duration of the experiment. While at a lower concentration (2.5 µg), the cells maintained a dose 
dependent cytostatic response for the duration of the experiment. Cytostatic drugs do not kill cancer 
cells but instead stop cells from proliferating. This is the first report of the promising selectivity and 
cytotoxicity of compound 7 for which data was collected using a viability dye and confirmed with  
RT-CES; this holds a great promise for use of this compound in chemo-preventive and 
chemotherapeutic strategies. 
Alismol (2) exhibited moderate cytotoxicity while Alismoxide (5) showed no toxicity in vitro, but 
data collected with xCELLigence showed the cytostatic effect of the compounds when tested at  
30 µg/mL and 100 µg/mL. 
As shown in Figure 5, it is clear that the compounds inhibited 50% of the cell proliferation 
compared to the untreated cells. The RT-CES diagram shows uptake of the compounds by the cells 
during the first h of incubation, later untreated cells proliferate (higher cell indices—CI) while cells 
incubated with compounds 2 and 5 do not show an increased CI, which can be interpreted as these 
compounds being cytostatic (anti-proliferative). This result supports the fact that RT-CES data is more 
reliable as it is not subjected to the shortcomings of the end point assays, such as sensitivity to 
environmental conditions or dependence on the cells’ metabolism of formazan [34]. 
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Figure 4. The effect of compound 7 on the proliferation of HeLa cells using RT-CES 
analysis. The compound displayed a dose dependent cytotoxic tendency at the IC50 
obtained by in vitro viability assay, and twice that amount. The lowest concentration, half 
of IC50 (2.5 µg/mL), displayed cytostatic effects when compared to the untreated cells 
grown in culture medium only. Actinomycin D (5.6 µM) was used as a positive control for 
cell death. 
 
Figure 5. The effect of compound 2 at 16 μg/mL and compound 5 at 60 μg/mL in HeLa 
cells were compared to the untreated cells (culture media only) and the positive control 
Actinomycin D. The compounds demonstrated cytostatic behavior (in the presence of these 
compounds, cells did not proliferate, nor did they die). 
 
2.4. Inhibitory Activities of HIV-1 Enzymes 
The isolated compounds were screened for their inhibitory activity against HIV-1 RT and HIV-1 
PR enzymes at 100 µg/mL. None of the compounds inhibited the HIV-1 RT enzyme, while, as shown 
in Figure 6 for HIV-1 PR, compounds Sarcophytol M (1), Chimyl alcohol (6) and and  
Erythro-N-dodecanoyl-docosasphinga-(4E,8E)-dienine (8) showed 100% inhibition. Compound 2 
showed inhibition of 96.2% while 7 demonstrated moderate inhibition of 71.5%. 
The fifty percent inhibitory concentrations (IC50s) were determined only for the compounds that 
inhibited more than 50% of the enzyme activity. The efficacy of the compounds was defined as potent 
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for compounds with IC50 < 5.6 µM as described by Cheenpracha et al., 2006 [35], weak compounds 
with IC50s > 10 µM as described in Marastoni et al., 1997 [36]. 
Figure 6. Protease inhibition of L. arboreum isolated compounds at 100 µg/mL. Fractions 
are indicated by number while the known inhibitor used as positive control, acetyl 
pepstatin is abbreviated AP. 
 
The detailed IC50 results expressed in Table 1, showed potent inhibitory activity of HIV-1 PR by 
compounds 7 (4.85 ± 0.18 µM), and 8 (IC50 4.80 ± 0.92 µM) compared to the positive control, which 
had IC50 of 8.5 ± 0.72 µM. Compound 2 showed moderate inhibitory activities with IC50  
(7.2 ± 0.70 µM). 
Sarcophytol M (1) and the Chimyl alcohol (6) showed weak inhibitory activities (15.7 ± 0.103 µM 
and 26.6 ± 2.6 μM). 
The cleavage of host cell proteins by HIV-1 PR results in cell death via several necrotic and 
apoptotic pathways, possibly leading to depletion of CD4 + T-cells. Thus, protease inhibitors are 
particularly useful, not only because they inhibit viral replication but also because they rescue host 
immune cells [37]. Potent PR inhibition were found in our bioassay for some of the tested compounds, 
compound 7 demonstrated activity at (IC50 4.85 µM). At this concentration, the compound showed 
50% cell death in HeLa and 20% cell death in U937 cells while it had no effect in Vero (normal cells) 
as the IC50 in these cells was 31.3 µM. On the other hand it was very interesting to find that,  
compound 8 (erythro-N-dodecanoyl-docosasphinga-(4E,8E)-dienine) was not toxic in any of the tested 
cell lines with IC50s 71 µM in HeLa, >100 µM in Vero cell lines and >100 µM in U937 and its effects 
in HeLa cells was confirmed with real time cell analysis as shown in Figure 7. Cells treated with a very 
high concentration (100 µg/mL) of compound 8 were only affected at long incubation times compared 
to the untreated cells. The mechanism of action of compound 8 is not known yet. The compound could 
be a very promising candidate for designing new lead compounds targeting HIV-1 infection, as the 
lipid rafts of the host cells primarily consist of sphingolipids and cholesterol and these have been 
implicated in the infectious route of HIV-1 entry. As lipid rafts are recognized sites for budding and 
entry of HIV-1, modulating the composition/structure of lipid rafts can influence the life cycle of  
HIV-1 inhibiting its replication [38]. 
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Figure 7. The effect of the active compound 8 on the proliferation of HeLa cells using  
RT-CES analysis. Cells treated with a high concentration (100 µg/mL) of compound 8 
showed low level cytotoxicity compared with the untreated cells grown in culture medium 
only and the positive control Actinomycin D.  
 
2.5. Molecular Docking 
In the 3D stereo-diagram of acetyl pepstatin bound to the HIV-1 protease active site shown in 
Figure 8, the X-ray structure clearly reveals that most of the amino acid moieties surrounding the 
inhibitor are hydrophobic. The figure was based on the X-ray crystal structure 5HVP available from 
the Protein Data Bank. The moieties that make up these pockets (among others) are Asp 25, Gly 27, 
Asp 29, Gly 48, Ile 50, and Thr 80, in each monomer, and as seen from the green color in the figure, 
which indicate the hydrophobic nature of the receptor pocket. 
Figure 8. 3D Stereo-diagram of the ligand “acetyl pepstatin” combined with the HIV-1 
protease receptor (5HVP) active site. The green color shows the lipophilic nature of  
the pocket. 
 
Figure 9 shows the interaction of the ligand and the bioactive compounds (1, 2, 6, 7, and 8). The 
ligand (acetyl pepstatin) interact through different hydrogen bonds with different amino acid moieties 
as shown in Table 2 and Figure 9 and scoring −24.79. In addition, Table 2 also shows the interaction 
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mode of bioactive compounds in the active site with different amino acid moieties with the 
corresponding measured bond distances. Interestingly, the compound containing an alkyl and an 
alkenyl chain gave a higher score, e.g., compound 6 (with long hydrocarbon chain) scored −17.16 
followed by compound 8 (containing two fatty chains) scored −15.92 and compound 1 (with a 
lipophilic backbone containing only a hydroxyl group) scored −14.44. In addition, this trend is very 
clear from the higher activity of compound 7 when compared to compound 9, which had only an extra 
acetyl group and a more lipophilic character. The data above indicated the importance of the 
hydrophobic part of different ligands when interacting in the binding pocket, and confirms the 
contribution of the hydrophobicity of inhibitors on HIV protease. Surprisingly, most of the nucleoside 
drugs in use are hydrophilic. Results presented here support the existing treatment strategies of using a 
combination of (hydrophilic and hydrophobic) drugs in the treatment of HIV. 
Figure 9. Interaction of bioactive compounds with different amino acid moieties in HIV-1 
protease receptor (5HVP) active site.  
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Figure 9. Cont. 
  
Table 2. Hydrogen bond types and scores of bioactive compounds interacting with HIV-1 
protease receptor (5HVP) active site. 
Ligand/Compound Residue Type Distance Score 
Ligand 
ASP 25 H-don 1.99 
−24.79 
ASP 25 H-don 2.72 
GLY 27 H-don 2.16 
ASP 29 H-don 1.95 
GLY 48 H-don 1.94 
ASP 25 H-acc 1.99 
ASP 25 H-acc 2.72 
ASP 29 H-acc 2.81 
1 
ASP 25 H-don 2.45 
−14.44 
ASP 25 H-acc 2.45 
2 
ASP 25 H-don 2.37 
−11.14 
ASP 25 H-acc 2.37 
6 
ILE 50 H-don 1.50 
−17.16 
GLY 52 H-don 1.65 
7 
THR 80 H-don 2.75 
−18.36 
THR 80 H-acc 2.75 
8 
ARG 8 H-Acc 2.61 
−15.92 
ARG 8 H-acc 3.01 
3. Experimental Section 
3.1. General Experimental Procedures 
The NMR spectra were recorded on Bruker spectrometer at 400 MHz for 1H and 100 MHz for 13C, 
and/or Varian “Mercury” 200 MHz, for 1H and 50 MHz for 13C in CDCl3 with TMS as internal 
standard. Chemical shifts are given in δ (ppm) and coupling constants in Hertz. EIMS were recorded 
by a Shimadzu Qp-2010 plus. Cytotoxicity plates red by BIOTEK Power-Wave XS multiwell plate 
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reader was used for the cytotoxicity assays. Pre-coated Si gel plates (Merck, Johannesburg, South 
Africa, Kieselgel 60 F254, 0.25 mm) were used for analytical TLC analyses. Silica gel 60 (Merck, 
Johannesburg, South Africa, 230–400 mesh) and Sephadex LH-20 from Pharmacia Fine Chemicals 
AB (Uppsala, Sweden) were used for column chromatography. Methanol, Dichloromethane, Ethyl 
acetate and DMSO, were obtained from Merck (Johannesburg, South Africa). All cell lines, media, 
trypsin-EDTA, fetal bovine serum (FBS), and antibiotics (penicillin, streptomycin, and fungizone) 
were supplied by Highveld Biological (Pty) Ltd. (Modderfontein, Johannesburg, South Africa). A 
puriﬁed recombinant HIV1-RT (Merck, Darmstadt, Germany) was used with the cell free reverse 
transcriptase colorimetric kit (Roche Diagnostics, Mannheim, Germany). The HIV-1 protease enzyme 
(Bachem Bioscience Inc., King of Prussia, PA, USA) and the substrate (a synthetic peptide that 
contains a cleavage site Tyr-Pro for HIV protease, as well as two covalently modiﬁed amino acids for 
the detection of cleavage) were used. 
3.2. Animal Material 
The soft coral L. arboreum was collected at Sharm El-Sheikh (Red Sea, Egypt), in May 2010, at a 
depth of 2–3 m, the tissue was kept in MeOH and extracted in situ. The material was collected and 
identified by Mona Ellithey, co-author of this article. 
3.3. Purification of the Active Constituents 
The sliced bodies of Litophyton arboreum (2 kg, fresh material) were blended with MeOH, after 
filtration the residue was washed twice with fresh MeOH. The total extracts were concentrated under a 
vacuum, and partitioned between EtOAc and H2O. The solvent-free EtOAc fraction (25 g) was 
subjected to column chromatography on silica gel and eluted with mixtures of increasing polarity from 
hexane and EtOAc (0%–100%) to yield 43 fractions, which were pooled together according to the 
TLC profile to twenty main fractions. 
The twenty fractions (1–20) were tested for their cytotoxic activity on U937 cell line at 100 µg/mL. 
The main fractions 5–8, 11, 12, 14, 15, and 20 showed potent cytotoxicity (Figure 1) and were 
subjected to chromatographic purification. Fraction 5 was chromatographed (on silica gel using 
hexane/EtOAc (98:2)) producing compound 1 (60 mg). Fraction 6 under the same conditions yielded 
pure 2 (750 mg). Fraction 7 was chromatographed (on silica gel using hexane/EtOAc (95:5)) 
producing compound 3 (40.2 mg). Fractions 8 was chromatographed [on silica gel] and produced 
transparent oily pure compound 4 (650 mg). Fraction 11 on standing at room temperature for three 
weeks produced crystals, which were washed with a mixture of hexane and EtOAc and produced pure 
compound 5 (1.2 g). Fraction 12 was chromatographed (on silica gel using gradient mixture of 
hexane/EtOAc (80:20 to 70:30)) producing compound 6 (200 mg). Fraction 14 was chromatographed 
(on silica gel using mixture of hexane/EtOAc (75:25)) producing compounds 7 (50 mg) and 8 (75 mg). 
Fraction 20 was chromatographed (on silica gel using hexane/EtOAc (70:30)) producing compound 9 
(20 mg). 
Sarcophytol M (1): Oil, [α]20D  +34 (c.0.76 CHCl3,); 
1
H NMR, (200 MHz, CDCl3) δH 5.25 (1H, t,  
J = 6.8 Hz, H-3); 4.91 (1H, t, J = 7.8 Hz, H-11); 4.89 (1H, t, J = 6.8 Hz, H-7); 1.61 (3H, s, Me-20); 
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1.59 (3H, m, H-19), 1.56 (3H, s, Me-18); 0.96, 0.94 (3H each, d, J = 6.8; Me-16, 17). 
13
C-NMR  
(50 MHz, CDCl3) δC 136.7 (C-4), 135.5 (C-12), 133.3 (C-8), 125.9 (CH, C-7), 123.2 (CH, C-11), 
120.9 (CH, C-3), 76.9 (C-1), 39.9 (CH2, C-9), 39.5 (CH2, C-5), 35.0 (CH2, C-14), 34.8 (CH2, C-2), 
34.6 (CH, C-15), 33.5 (CH2, C-13), 24.8 (CH2, C-6), 23.7 (CH2, C-10), 16.9 (CH3, C-17), 16.6 (CH3, 
C-16), 16.2 (CH3, C-20), 15.4 (CH3, C-19), 15.2 (CH3, C-18) [12]. 
Alismol (2): Oil; [α]20D  +4.9 (c.0.2 CHCl3,); 
1
H NMR (200 MHz, CDCl3): δH 5.56 (1H, s, H-6), 
4.69,4.64 (1H each, s, H2-14); 1.17 (3H, s, Me-15), 0.93, 0.92 (3H each, d, J = 6.6 Hz, Me-13, 14); 
13
C 
NMR (50 MHz, CDCl3): δC 153.9 (C-10), 149.3 (C-7), 121.4 (CH, C-6), 106.4(CH2, C-15), 80.4 (C-4), 
54.6 (CH, C-1), 47.0 (CH, C-5), 40.0 (CH2, C-3), 37.3 (CH, C-11), 36.9 (CH2, C-9), 29.8 (CH2, C-8), 
24.6 (CH2, C-2), 23.8 (CH3, C-14), 21.3 (CH3, C-13), 21.1(CH3, C-12) [13,14]. 
24-Methyl-cholesta-5,24(28)-diene-3β-ol (3): [α] 25D  +7.2° (c 0.3 CHCl3); 
1
H NMR (400 MHz, 
CDCl3) δH 0.65 (3H, br s, H-18), 0.92 (3H, d, J= 6.18, H-21), 0.97 (3H, br s, H-19), 1.00 (3H, d,  
J = Hz, H-27), 0.98, 1.00 (3H, d, J= Hz, H-26), 3.51 (1H, br s, H-3), 4.63 (1H, s, H-28a), 4.69 (1H, s, 
H-28b), 5.32 (1H, s, H-6). 
13
C NMR (100 MHz, CDCl3) data: δC 157.3 (C-24), 141.2 (C-5), 122.1 
(CH, C-6), 106.4 (CH2, C-28), 72.1 (CH, C-3), 57.2 (CH, C-14), 56.4 (CH, C-17), 50.5 (CH, C-9), 
42.6 (C-13), 42.8 (CH2, C-4), 40.1 (CH2, C-12), 37.7 (CH2, C-1), 36.2 (C-10), 35.7 (CH, C-20), 35.1 
(CH2, C-23), 34.2 (CH, C-25), 32.3 (CH, C-8), 32.0 (CH2, C-7), 32.0 (CH2, C-2), 31.4 (CH2, C-22), 
28.6 (CH2, C-16), 24.7 (CH2, C-15), 22.4 (CH3, C-27), 22.3 (CH3, C-26), 21.5 (CH2, C-11), 19.8 (CH3,  
C-19), 19.1 (CH3, C-21), 12.3 (CH3, C-18) [15]. 
10-O-Methyl alismoxide (4): Oil, [α]20D  +5.9° (c 0.3 CHCl3). 
1
H NMR (200 MHz, CDCl3) δH 5.41 
(1H, br s, H-6), 3.12 (OMe); 1.13, 1.14 (3H each, s, Me-14, 15); 0.93, 0.90 (3H each, d, J = 6.6 Hz, 
Me-12, 13); 
13
C NMR (50 MHz, CDCl3): δC 149.5(C-7), 121.2 (CH, C-6), 80.1 (C-4), 79.2(C-10), 50.0 
(CH, C-5), 48.6 (OCH3), 47.8 (CH, C-1), 40.4 (CH2, C-3), 37.1(CH, C-11), 35.4(CH2, C-9), 24.5(CH2, 
C-8), 22.3(CH3, C-14), 21.6 (CH2, C-2), 21.5 (CH3, C-13), 21.2 (CH3, C-12), 17.9 (CH3,  
C-15) [13,16]. 
Alismoxide (5): Colorless crystals, mp 138–141 °C; [α]20D  +9.3 (c 0.9 CHCl3,) 
1
H NMR (400 MHz, 
CDCl3) δH 5.44 (1H, br d, J = 3.0 Hz, H-6), 0.98, 1.0 (3H each, d, J = 6.9 Hz, H-12, 13), 1.25, 128 (3H 
each, s, H-14,15);
13
C NMR (100 MHz, CDCl3): δC 149.4(C-7), 121.3 (CH, C-6), 80.0 (C-4), 75.2  
(C-10), 50.5 (CH, C-1), 50.1 (CH, C-5), 42.5 (CH2, C-9), 40.3 (CH2, C-3), 37.2 (CH, C-11), 25.0 
(CH2, C-8), 22.4 (CH3, C-14), 21.4 (CH2, C-2), 21.3 (CH3, C-15), 21.2 (CH3, C-13), 21.1 (CH3, C-12). 
Chimyl alcohol (6): [α]20D  +7.2° (c 0.3 CHCl3); 
1
H NMR (CDCl3, 200 MHz) δH, 3.83 (1 H, m, H-2), 
3.72, 3.64 (2H, m, H-1), 3.45 (4H, m, H-1′, 3), 1.52 (2H, m, 2′-H2), 1.26 (26H, br s, CH2), 0.84 (3H, t, 
J = 6.6 Hz, CH3); 
13
C NMR (50 MHz, CDCl3): δC 72.4 (CH2-1′), 71.8 (CH2-1), 70.5 (CH-2), 64.2 
(CH2-3), 31.9 (CH2-13′), 29.7-29.3 (CH2′s), 26.0 (CH2-3′), 22.7 (CH2-14′), 14.1 (CH3). HRESIMS: 
317.3045 [M + H]
+
 corresponding to C19H41O3, calculated for 317.3057 [13,14]. 
7β-Acetoxy-24-methyl-cholesta-5,24(28)-diene-3β,19-diol (7): Amorphous powder, [α] 20D  +6.7°  
(c 0.5 CHCl3); 
1
H NMR (400 MHz, CDCl3): δH 5.56 (1H, t, J = 2 Hz, H-6), 4.95 (1H, dt, J = 2.2, 2.2,  
8.5 Hz, H-7α), 4.70 (1H, t, J = 1.3 Hz, HA-28), 4.64 (1H, dd, J = 1.3 and 1.7 Hz, HB-28), 3.87 (1H, d,  
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J = 11.5 Hz, HA-19), 3.64 (1H, d, J = 11.5 Hz, HB-19), 3.59 (1H, tt, J = 11.2 4.7 Hz, H-3α), 2.38 (1H, 
ddd, J = 13.5, 4.7, 2.4 Hz, H-4α), 2.01 (3H, s, OAc), 1.01 (3H, d, J = 6.8 Hz, Me-26), 1.00 (3H, d,  
J = 6.8 Hz, Me-27), 0.93 (3H, d, J = 6.8 Hz, Me-21), 0.73 (3H, s, Me-18). 
13
C NMR (100 MHz, 
CDCl3): δC 171.4 (MeCOO-), 156.7 (C-24), 140.1 (C-5), 126.6 (CH, C-6), 106.0 (CH2, C-28), 75.2 
(CH, C-7), 70.8 (CH, C-3), 62.8 (CH2, C-19), 56.5 (CH, C-14), 55.2 (CH, C-17), 48.5 (CH, C-9), 43.1 
(C-13), 41.6 (CH2, C-4), 41.4 (qC, C-10), 39.7 (CH2, C-12), 37.8 (CH, C-8), 35.6 (CH, C-20), 34.6 
(CH2, C-22), 33.7 (CH, C-25), 33.1 (CH2, C-1), 31.7 (CH2, C-2), 30.9 (CH2, C-23), 28.3 (CH2, C-16), 
24.9 (CH2, C-15), 22.0 (CH3, C-26), 21.8 (CH3, C-27), 21.7 (CH3, CH3COO), 21.6 (CH2, C-11), 18.7 
(CH3, C-21), 12.1 (CH3, C-18) [18]. 
Erythro-N-dodecanoyl-docosasphinga-(4E,8E)-dienine (8): 
1
H NMR (400 MHz, CDCl3): δH 6.25 
(1H, d, JNH,2 = 7.6 Hz; H-NH), 5.78 (1H, dtd, J = 15.4, 6.4, 1.2 Hz; H-5), 5.54 (1H, ddt, J = 15.4, 6.3, 
1.3 Hz; H-4), 5.42 (1H, dt, J = 15.3, 6.3 Hz; H-9), 5.36 (1H, dt, J = 15.3, 5.9 Hz; H-8), 4.32 (1H, br, 
apparently triplet, J = 4.9, 6.3, 1.2 Hz; H-3 (please note that the J values were measured in the other 
coupled protons)), 3.95 (1H, dd, J = 11.0, 3.2 Hz; HA-1), 3.90 (1H, dddd, J = 3.2, 3.2, 4.9 Hz,  
J2,NH = 7.6 Hz; H-2), 3.70 (1H, dd J = 11.0, 3.2 Hz; HB-1), 2.23 (2H, t, J = 7.4 Hz; 2H-2′), 2.12 (2H, 
m; 2H-6), 2.08 (2H, m; 2H-7), 1.96 (2H, q, J = 6.4, 6.4 Hz; 2H-10), 1.64 (4H, m; 2H-3′ and 2H-of 
other position), 1.25 (-(CH2)n-), 0.88 (6H, t, Jvic = 7.0 Hz; Me-22 and Me-16′); 
13
C NMR (100 MHz, 
CDCl3): δC 173.9 (C-1′), 133.5 (CH, C-5), 131.6 (CH, C-9), 129.2 (CH, C-4), 129.0 (CH, C-8), 74.7 
(CH, C-3), 62.5 (CH2, C-1), 54.4 (CH, C-2), 36.8 (CH2, C-2′), 32.6 (CH2, C-10), 32.3–31.9 (all CH2), 
29.7–29.1 (all CH2), 25.8 (2CH2, C-3′ and other CH2), 22.7 (2CH2, C-21 and C-15′), 14.1 (2CH3,  
C-22 and C-16′). HRESIMS: found 536.5040 [M + H]+, calculated for C34H66NO3 536.50458 [19]. 
24-Methyl-cholesta-5,24(28)-diene-3β,7β,19-triol (9): Amorphous powder, [α]20D  +5.2° (c 0.2 MeOH). 
1
H-NMR [200 MHz, CDCl3/CD3OD (1:3)] δH 5.44 (1H, s, H-6), 4.67, 4.61 (1H each, br s, H2-28) 
3.54, 3.80 (1H each, d, J = 11.8 Hz, H-19), 3.60 (1H, br s, H-7), 3.42 (1H, m, H-3), 0.94 (6H, d,  
J = 7.0 Hz, Me-26, 27), 0.92 (3H, d, J= 6.6, Me-21), 0.72 (3H, br s, Me-18),. 
13
C-NMR [50 MHz, 
CDCl3/CD3OD (1:3)] δC 157.7 (C-24), 140.0 (C-5), 131.0 (CH, C-6), 106.9 (CH2, C-28), 73.3 (CH,  
C-7), 72.0 (CH, C-3), 63.4 (CH2, C-19), 58.6 (C-14), 56.8 (CH, C-17), 49.8 (CH, C-9), 44.3 (C-10), 
42.7 (CH2, C-4), 42.4 (CH, C-8), 42.4 (C-13), 41.5 (CH2, C-12), 37.0 (CH, C-20), 36.0 (CH2, C-22), 
34.9 (CH, C-25), 34.0 (CH2, C-1), 32.6 (CH, C-2), 32.1 (CH2, C-23), 29.7 (CH2, C-16) 27.2 (CH2,  
C-15), 22.9 (CH2, C-11), 22.5 (CH3, C-26), 22.3 (CH3, C-27), 19.3 (CH3, C-21), 12.6 (CH3,  
C-18) [20]. 
3.4. HIV-1 Direct Enzyme Assays 
Reverse transcriptase (RT) inhibitory activity of the crude extracts against a puriﬁed recombinant 
HIV1-RT (Merck, Darmstadt, Germany) was determined by using the Roche Diagnostics (Mannheim, 
Germany) colorimetric kit. The assay was performed as previously described [34]. 
HIV-1 protease enzyme was purchased from Bachem Bioscience Inc. King of Prussia, PA, UK and 
the substrate (a synthetic peptide that contains a cleavage site Tyr-Pro for HIV protease as well as two 
covalently modiﬁed amino acids for the detection of cleavage). The assay was performed according to 
procedures by Lam et al., 2000 [39], in black 96 well assay plates obtained from Corning Incorporated, 
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(Corning, New York, NY, USA). The fluorescence intensity was measured at an excitation wavelength 
of 355 nm and an emission wavelength of 460 nm using a synergy microplate spectrofluorometer 
(BioTek, Analytical & Diagnostic products, South Africa). Acetyl pepstatin (AP) was used as a 
positive control for HIV-1 PR inhibition. DMSO was included in the enzyme control (1% DMSO). 
Enzyme remains active after this addition as observed from the fluorescent values obtained. The 
percentage inhibition was calculated based on the formula: 100 − [(Test reagent RFU − background 
RFU)/(untreated control RFU − blank) × 100] where RFU = relative fluorescence units. 
All the isolated compounds were screened at 100 µg/mL for inhibition of HIV-1 enzymes. IC50 
values of the most active extracts were calculated and compared to known HIV-1 PR and HIV-1 RT 
inhibitors as well as the untreated enzymes activities. All the experiments were repeated three times in 
order to ensure the precision and accuracy of the data. 
3.5. Cytotoxicity 
All cell lines, media, trypsin-EDTA, fetal bovine serum (FBS), phosphate buffer saline (PBS) and 
antibiotics were supplied by Highveld Biological (Pty) Ltd. (Modderfontein, Johannesburg,  
South Africa). 
HeLa, U937, and Vero cell lines were maintained in culture flasks containing Eagle’s Minimum 
Essential Medium supplemented with 10% heat-inactivated FBS and 1% antibiotics (100 U/mL 
penicillin, 100 μg/mL streptomycin, and 250 μg/mL fungizone). The cells were grown at 37 °C in a 
humidified incubator set at 5% CO2. Cells were subcultured after they formed a monolayer on the 
flask. The cells were detached by treating them with trypsin-EDTA (0.25% trypsin containing 0.01% 
EDTA) for 10 minutes and then by adding complete medium to inhibit the reaction. Cytotoxicity was 
measured by the XTT method using the Cell Proliferation Kit II. The method described by  
Zheng et al. [40] was used to perform the assay. Cells were seeded (100 μL) in a 96-well microtiter 
plate (concentration 1 × 10
5
 cells/mL). The plate was then incubated for 24 h at 37 °C and 5% CO2 to 
allow the cells to attach to the bottom of the wells. The compounds were each prepared to a stock 
solution of 20 mg/mL and added to the microtiter plate. Serial dilutions were made to range from a 
concentration of 100 μg/mL–0.7 μg/mL for each compound. The microtiter plate was incubated for a 
further 72 h. The control wells included vehicle-treated cells exposed to 2% DMSO and the positive 
control Actinomycin D, with concentrations ranging between 0.5 μg/mL and 0.002 μg/mL. After the 
72 h incubation period, the XTT reagent (50 μL) was added to a final concentration of 0.3 mg/mL and 
the plate was then further incubated for another 2 h. After the incubation the absorbance of the color 
complex was read at 490 nm with a reference wavelength set at 690 nm. Mean IC50 is the 
concentration of compound, which reduces cell growth by 50% under the experimental conditions and 
is the average of at least three independent reproducible statistically significant measurements. The 
IC50 values were reported at ±95% confidence intervals (±95% CI). The results were analyzed using 
the GraphPad Prism 4 program. 
3.6. Real-Time Cell Electronic Sensing (RT-CES) xCELLigence 
The xCELLigence system was used according to the instructions of the supplier (Roche 
Diagnostics, Mannheim, Germany and ACEA Biosciences, San Diego, CA, USA). HeLa cell line, 
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media, trypsin-EDTA, fetal bovine serum (FBS), phosphate buffer saline (PBS), and antibiotics were 
supplied by Highveld Biological (Pty) Ltd. (Modderfontein, Johannesburg, South Africa). 
The xCELLigence system was used according to the instructions of the supplier (Roche 
Diagnostics, Mannheim, Germany and ACEA Biosciences, San Diego, CA, USA). [41]. 
The electronic impedance of sensor electrodes that connect the E plate to the instrument is 
measured to allow monitoring and detection of physiological changes of the cells on the electrodes. 
The impedance measured between electrodes in an individual well depends on electrode geometry, ion 
concentration in the well and whether or not cells are attached to the electrodes. In the absence of cells, 
electrode impedance is mainly determined by the ion environment, both at the electrode/solution 
interface, and in the bulk solution. In the presence of cells, cells attached to the electrode sensor 
surfaces will act as insulators and thereby alter the local ion environment at the electrode/solution 
interface, leading to an increase in impedance [41]. Thus, the more cells that are growing on the 
electrodes, the larger the value of electrode impedance. This assay has been described for the 
measurement of cytotoxicity [42,43] and can be used to determine other cellular parameters such as 
cell proliferation, cytotoxicity start time, cell recovery, and cell response patterns [44] in real time. 
HeLa cells were grown and expanded in tissue-culture flasks. After reaching ~75% confluence, the 
HeLa were washed with PBS, and afterwards detached from the flasks by a brief treatment with 
trypsin. Subsequently, 50 µL of cell culture media at room temperature was added into each well of  
E-plate. After this the plate was connected to the system and checked in the cell culture incubator for 
proper electrical-contacts and the background impedance was measured over 24 h. Meanwhile, the 
cells were re-suspended in cell culture medium and adjusted to 2 × 10
5
, 1 × 10
5
, 5 × 10
4
, and  
2.5 × 10
4
 cells/mL. One-hundred microliters of each cell suspension was added to the 50 µL medium 
containing wells on the E-plate, in order to determine the optimum cell concentration. After 30 min 
incubation at room temperature, E-plates were placed into the cell culture incubator. Finally, adhesion, 
growth, and proliferation of the cells was monitored every 30 min for a period of up to 18 h via the 
incorporated sensor electrode arrays of the E-Plate. The electrical impedance was measured by the 
RTCA-integrated software of the xCELLigence system as a dimensionless parameter termed Cell 
index (CI). After determining the optimal concentration for HeLa cells proliferation, cells at the 
optimal concentration were seeded in 100 µL in each well of the E-plate, the proliferation, attachment, 
and spreading of the cells was monitored every 30 min by the xCELLigence system. Approximately  
30 h after seeding, when the cell index was 1.5 (in the log growth phase), cells were then treated with 
the compounds at the IC50 obtained by XTT. The positive control Actinomycin D, with concentrations 
ranging between 0.5 μg/mL and 0.002 μg/mL, was also tested and just cells growing in the culture 
medium were included as (untreated cells) or negative control. All experiments were run for 72 h after 
adding the compounds. All calculations were obtained using the RTCA-integrated software of the 
xCELLigence system. 
3.7. Molecular Docking 
For the purpose of lead optimization and to find out the interaction between the compound and the 
HIV-1 protease receptor, molecular modeling calculations and local docking were done using MOE. 
This was done to evaluate the binding free energies of this inhibitor into the target HIV-1 protease 
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receptor, and to find out interactions between ligand and receptor, also, to compare affinities of the 
isolated bioactive compounds to the target HIV-1 protease receptor. For the docking calculations, the 
protein structure (PDB code: 5HVP) [45] was first separated from the inhibitor molecule and refined 
using molecular minimization with added hydrogen. 
Docking calculations were carried out using standard default variables for the MOE program. The 
binding affinity was evaluated by the binding free energies (S-score, kcal/mol), hydrogen bonds, and 
RMSD values. The compounds were docked into the same groove of the binding site of the native  
co-crystallize ligand. The Dock scoring was performed with the London dG scoring function and has 
been enhanced using two different refinement methods, which were capable of sampling 
conformational changes in the backbone structure. We allowed rotatable bonds; the best 10 poses were 
retained and analyzed for the binding poses best score. Energy minimization was done through  
Force-field MMFF94x Optimization using gradient of 0.0001 for determining low energy 
conformations with the most favorable (lowest energy) geometry. 
4. Conclusions 
In this study, we report for the first time, the isolation, identification and biological evaluation of 
metabolites from L. arboreum collected from Sharm El sheikh (Red Sea). L. arboreum extract 
collected from the southern part of the Red Sea showed more promising cytotoxic metabolites than that 
of the same organism collected from the South China Sea [10]. A possible reason for this could be 
spatial and temporal variations in secondary metabolites from organisms from different geographical 
regions. Potencies of the metabolites produced by an organism may also differ based on the stress 
experienced by the organism in a particular environment [46]. This report is also the first to provide 
data on L. arboreum extract and the purified compounds demonstrating anti HIV-1 activities where 
some of the isolated metabolites exhibited potent anti-HIV-1 protease activity with low or no 
cytotoxicity. Some of the isolated metabolites demonstrated cytostatic activities, which suggest further 
investigation of their use in concert with anti-viral drugs where the cytostatic compound arrests cell 
growth while the antiviral drug inhibits viral replication. It was mostly the polyhydroxylated-isolated 
metabolites that showed strong cytotoxicity and high selectivity in the cancer cells used in this study. 
The high cytotoxicity of polyhydroxylated sterols from marine organisms is well reported and 
supported by data presented here and highlights the importance of this skeleton in developing potential 
lead compounds from marine sources. Taking into consideration the advantage of the chemical 
structure similarity of these compounds to the human sterols, polyhydroxysterols can be considered as 
potential lead compounds for the development of new, safe, and effective medicines. Further studies 
on this type of active compound scaffold using structure activity relationship (SAR) modeling, could 
lead to the production of new compounds with even better activities and drug-like properties. 
The biological activities of the L. arboreum metabolites have not been extensively studied meaning 
these metabolites may yet demonstrate additional biological activities. The compounds isolated from 
L. arboreum have been isolated from terrestrial organisms as well but appear to demonstrate more 
varied functionalities when isolated from a marine environment. If further investigation strongly 
indicates clinical value, the supply of active materials will have to be addressed by synthesis rather 
than continued isolation from live organisms, which is why SAR studies are crucial. 
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